Provider review
Luvo Health review: a hedged weight-loss timeline, and longevity promises no product owns
Almost every seller we grade compresses the timeline. One promises 18% of your body weight gone by week 24; another says full results arrive in two to three months. The trials behind these drugs ran 68 and 72 weeks. Luvo Health calls months two to three the point of first improvements, not the finish, attaches no percentage to it, and says progress varies by individual. That is a hedged timeline in a market that rarely hedges. The problem is the longevity program: it lists sermorelin, three forms of NAD+ and vitamin B12/MIC, then promises better energy, balanced hormones and healthier cells for the program as a whole, without saying which product is meant to do which.
Partner link — we may earn a commission. How we’re paid
Visit Luvo HealthOf Luvo Health’s 3 dated product claims documented below, 2 are consistent with the cited evidence. Among the dated prices documented below, the lowest listed upfront charge is $145 for 28 days (Longevity program, lowest starting rate, billed every four weeks). A matching claim does not mean the compounded product was tested or FDA-approved.
A weight-loss timeline hedged the way the trials would hedge it — and a longevity program that promises five benefits without saying which of its products delivers any of them.
Worth trusting if
- You want a seller that treats the first few months as a beginning, not a result
- You want outcome language hedged honestly, which this site does throughout
- You are buying the GLP-1 program, where the compounds are named and the evidence is strong
Be skeptical if
- You are buying the longevity program and want to know which product is meant to deliver which benefit
- You budget by the calendar month, because every plan here is billed every four weeks — thirteen charges a year
- You want the pharmacy or the prescribing clinician named
Disclosure: Some links on this site are affiliate or referral links. If you start a treatment or buy a product through them, we may earn a commission at no additional cost to you. Read our full disclosure.
Compounded
Phase 3 trials
Not confirmed
None found
Provenance
Products reviewed at Luvo Health
These evidence cards classify the treatments evaluated in this review. Confirm the exact medicine and formulation proposed for your prescription with the care team.
Prepared by a state-licensed pharmacy against a prescription for a named patient. Compounded preparations are not FDA-approved and are not reviewed by FDA for safety, effectiveness or quality.
- Compounded semaglutide injection — $209 every four weeks, after a half-price first four weeks at $104.50. Billed every 28 days, a full year at that rate is $2,717.
- Compounded tirzepatide injection — $249 every four weeks, after a half-price first four weeks at $124.50 — $3,237 for a full year on the same 28-day billing.
- Longevity program — From $145 to $199 every four weeks to start, depending on the treatment.
Evidence
Has the molecule been tested for what it is sold for?
Each row summarizes human evidence for the molecule and the use being advertised. Results apply to the product, dose, population and outcome studied; they do not establish that this provider’s preparation or program produces the same results. Compounded drugs are not FDA-approved. Evidence for one use should not be assumed to support another.
2
Products with human evidence
For the advertised use, out of 3 products reviewed here. The evidence concerns the molecule, not Luvo Health's service.
2
Registry records cited
Distinct ClinicalTrials.gov records cited across the reviewed products. Registration alone does not establish that a treatment works.
The comparison
What they claim, against what the trials show
Each claim below is quoted word for word from Luvo Health’s own page. Tap a row to see the quote, the trials behind it, and why it got that verdict.
Compounded semaglutide injectionSemaglutide · Compounded (503A)Claim matches the trials
“Clinically guided weight care — built around you. Progress varies by individual. Some changes may be noticed over time, while longer-term outcomes depend on consistency, clinical factors, and individual response. MONTH 2–3: First improvements. People notice steady changes as their approach becomes more consistent.”
Read on the Luvo Health site, September 2026
Phase 3 trials
What the trials show for Semaglutide
- NCT03548935 STEP 1 — Phase 3, completed, n=1,961. 68 weeks in 1,961 adults, titrated to semaglutide 2.4 mg. Weight was still falling at the end of the trial, which is why a timeline that treats months two to three as a beginning, not a result, fits it.
A defensible timeline, because it claims so little. STEP 1 ran 68 weeks and its weight curve was still descending at the end, so calling months two to three the point of first improvements, and describing everything after as ongoing progress, fits the published shape of the response. Luvo attaches no percentage and no pounds figure to any stage, and says outright that progress varies and that longer-term outcomes depend on consistency. The one line that reaches too far is the promise of safe results without extremes: safety is not a property this site can confirm for a compounded preparation, and Luvo's own copy elsewhere correctly leaves that judgment to a clinician.1
Compounded tirzepatide injectionTirzepatide · Compounded (503A)Claim matches the trials
“Personalized weight loss support guided by licensed clinicians and evidence-based protocols. Your care plan is tailored to you and may evolve over time based on response, tolerability, and clinical review.”
Read on the Luvo Health site, September 2026
Phase 3 trials
What the trials show for Tirzepatide
- NCT04184622 SURMOUNT-1 — Phase 3, completed, n=2,539. 72 weeks in 2,539 adults at 5, 10 and 15 mg once weekly, mean reduction of roughly 21% at the top dose.
Nothing here reaches past SURMOUNT-1, because nothing here quantifies anything. Luvo describes the service — a clinician-guided plan that changes with your response and tolerability — and makes no promise about the result. Describing the protocols as evidence-based is fair for these two molecules, whose trial record is genuinely strong, though the phrase does a lot of work on a site that also sells products it declines to name.2
Longevity programLongevity program (sermorelin, NAD+, vitamin B12/MIC) · Compounded (503A)No trial supports this claim
“Support metabolic and cellular health. Boost energy — supports overall vitality and wellbeing, and improve physical resilience. Balance hormones and metabolism — supports natural hormone production and metabolic health. Address modifiable risk factors associated with aging. Providers may recommend prescription treatments from licensed pharmacies.”
Read on the Luvo Health site, September 2026
No trial for this use
No trial can be matched to these claims because Luvo makes them for the program, not for a product. Read in September 2026 on its own site, the longevity page lists sermorelin, an NAD+ injection, NAD+ drops, an NAD+ spray and a vitamin B12/MIC injection, with BPC-157 marked coming soon, and states its five benefits above that list without assigning any of them to any product or giving a dose. A trial record belongs to one molecule studied for one use; attaching one to a program-wide promise would be choosing the evidence on Luvo's behalf.
Five benefit claims, five products, and no line between them. Supporting cellular health, boosting energy, balancing hormones and addressing modifiable risk factors of aging are the four things this whole category promises, and every one of them is a claim about an effect on a body — the kind that has to be tied to a specific drug before anyone can weigh it. Luvo names the drugs and then makes the promises for the program as a whole, so a reader cannot tell whether energy is meant to come from NAD+, hormone balance from sermorelin, or all of it from any of them. Calling the options evidence-based without saying which evidence, or for which product, is the part that fails.
Dispensing chain
Who actually fills your prescription
Read the full account
No pharmacy is named and no compounding tier is stated, so nothing tells you whether your medication is made to order under your prescription or dispensed ready-made. No individual clinician is named either — the site refers throughout to a licensed healthcare provider who reviews your information and decides whether treatment is appropriate. The one named professional anywhere on the property is an article byline in its longevity library, a pharmacist credited on a piece about what to realistically expect from a peptide. That is a more careful use of a named expert than most of this market manages, and it is not the same as naming the person who would write your prescription.
Read on the Luvo Health site, September 2026.
Quality
Third-party testing, and what is published
Describes a testing regime
Not established in this source review
Certificate of analysis readable
A readable lot report was not verified here
Read the full testing account
No certificate of analysis, potency, purity or sterility result appears anywhere. What Luvo publishes instead is restrained language about outcomes — progress varies by individual, weight change builds over months, results require time and effort — and an editorial library whose articles are bylined by a named pharmacist. Set against that is a longevity program whose benefits are described in five bullet points that no product on its list is tied to, and a promise of safe, sustainable results that no published evidence on compounded preparations supports.
Read on the Luvo Health site, September 2026.
Licensing
Licensed to dispense, and where
Coverage
Luvo publishes no list of states, no included set and no exclusions, checked in September 2026 across the weight-loss and longevity program pages and the pricing blocks on each. Nothing on the site tells you whether your own state is served before you begin.
Read the full licensing claim
No operating company is named on the pages read, and no individual clinician is identified. The site describes a licensed healthcare provider reviewing each intake and determining whether treatment is appropriate, which is the correct process and not a disclosure of who performs it.
Read on the Luvo Health site, September 2026.
Regulatory
The FDA warning letter
No FDA warning letter found
Assessment
What holds up, and what does not
- Its weight-loss timeline calls months two to three the start of improvement, not the finish, which fits how the trials actually ran.
- It says plainly that progress varies by individual and that weight change builds over months, rather than promising a fast outcome.
- It attaches no weight-loss percentage or pounds figure to either GLP-1 product.
Show 5 more
- It states that a clinician decides whether treatment is appropriate, and repeats it at each step.
- Its care plan is described as changing with your response and tolerability, not fixed at signup.
- It names every product in its longevity program: sermorelin, three forms of NAD+ and vitamin B12/MIC.
- Its articles are bylined by a named pharmacist.
- No FDA warning letter.
- Its longevity program makes five benefit claims for the program as a whole and ties none of them to a named product.
- It calls those options evidence-based without saying which evidence, or for which product.
- "Safe, sustainable results" is a safety claim no published evidence on compounded products supports.
Show 4 more
- Plans bill every four weeks, so a year is thirteen charges, not twelve.
- No pharmacy is named, and nothing says whether your medication is made to order.
- No prescribing clinician is named.
- No list of served states is published anywhere.
Verdict
The bottom line
Buy the weight-loss program if honesty about timing matters to you, because Luvo claims less than almost anyone selling the same drugs. Do not buy the longevity program without asking which of its products you would be prescribed and what that product has been tested for — five promises about your cells, made for a menu rather than a drug, are not something anyone can check, including us.
Opens Luvo Health's website. A link is not a recommendation to take anything.
Cancellation and follow-up
Checked October 13: Luvo says patients can pause or cancel through their account, generally before an order begins processing. That cutoff matters more than the phrase cancel anytime: stopping a later renewal does not establish that the current order can be refunded. The homepage also says most programs include check-ins and non-urgent care-team messaging, with labs required or recommended for some services. 3
Ask when the next order enters processing, whether your quote includes required laboratory work and which clinician handles side-effect questions. These are public service promises; we have not tested the intake or support response time.
Full analysis — 4 more sectionsIt gets the timeline right · And then the program that won't match its promises to its products · The one line that reaches too far · A note on the price
It gets the timeline right
Here is what other sellers promise:
- 18% of body weight by week 24. (Two different brands, same template.)
- "Full results for most programs develop over 2–3 months."
STEP 1 ran 68 weeks. 1 SURMOUNT-1 ran 72 weeks. 2 In both, weight was still falling at the end.
Here is Luvo:
"Progress varies by individual. Some changes may be noticed over time, while longer-term outcomes depend on consistency, clinical factors, and individual response."
"MONTH 2–3 · First improvements"
"3+ MONTHS · Sustainable progress"
And in its FAQ: "Weight change typically builds over months and varies by individual."
Months two to three is where the improvement starts, not where it ends, and no stage carries a percentage or a pounds figure. That is a hedged timeline, and it runs in the direction the evidence does.
And then the program that won't match its promises to its products
Luvo's longevity service promises five things:
"Support metabolic and cellular health."
"Boost energy — supports overall vitality and wellbeing, and improve physical resilience."
"Balance hormones and metabolism — supports natural hormone production and metabolic health."
"Address modifiable risk factors associated with aging."
"Build sustainable habits that compound over time."
Further down the same page, it lists what it prescribes: sermorelin, an NAD+ injection, NAD+ drops, an NAD+ spray and a vitamin B12/MIC injection, with BPC-157 marked coming soon.
What the page never does is connect the two lists. No benefit is assigned to any product, and no product page is cited for any benefit.
Four of those five promises are claims about an effect on a body. Each one needs to be tied to a specific drug before anybody — a reader, a clinician, or us — can weigh it. Is the energy meant to come from NAD+? The hormone balance from sermorelin? Luvo calls the options "evidence-based" without saying which evidence belongs to which product.
That is also the program this company's affiliate listing points at by default.
The one line that reaches too far
"Safe, sustainable results — without extremes."
Safety is not a property anyone can confirm for a compounded preparation from a website, and Luvo's own copy elsewhere gets this right — it leaves the judgment to a clinician who reviews your history. The promise on the weight-loss page contradicts the process on the same page.
A note on the price
Luvo bills every four weeks, not every month: $209 for semaglutide and $249 for tirzepatide, after a half-price first four weeks. The longevity program starts at $145 to $199 depending on the treatment.
Four-week billing means thirteen charges a year, so a full year at the standing rate costs $2,717 for semaglutide and $3,237 for tirzepatide. The price does include the medication, the clinician and shipping, with no membership or consult fee on top.
Questions
Frequently asked questions
How long before Luvo's treatment works?
Luvo puts first improvements at months two to three and calls everything after that ongoing progress, with no percentage attached to any stage. Its FAQ adds that weight change typically builds over months and varies by individual. That framing fits the evidence: the trials behind these drugs ran 68 and 72 weeks with weight still falling at the end.
What is in the longevity program?
The longevity page lists sermorelin, NAD+ as an injection, drops or a spray, and a vitamin B12/MIC injection, with BPC-157 marked coming soon. It does not say which of those products is meant to deliver which of its five promised benefits, and it gives no doses. Ask which product you would be prescribed, and why, before ordering.
Is the treatment safe?
Nothing on the site establishes that, and the claim of safe results without extremes is the one line here that reaches past what anyone can support for a compounded preparation. Luvo's own process page gets it right by leaving that judgment to a clinician reviewing your history.
What does it cost?
Compounded semaglutide is $209 every four weeks and tirzepatide $249, each after a half-price first four weeks. Because the charge lands every 28 days, a full year at the standing rate is thirteen payments: $2,717 and $3,237. The longevity program starts at $145 to $199 every four weeks.
Who makes the medication?
Luvo doesn't name a pharmacy, and nothing says whether your medication is made to order under your prescription or dispensed ready-made. No prescribing clinician is named either, though the site does describe a licensed provider reviewing each intake.
Glossary
Key terms
Show definitions
- STEP 1
- The phase 3 trial of once-weekly semaglutide 2.4 mg for weight loss — 1,961 adults over 68 weeks, published in the New England Journal of Medicine in 2021.
- SURMOUNT-1
- The phase 3 trial of once-weekly tirzepatide for weight loss — 2,539 adults over 72 weeks at 5, 10 and 15 mg, published in the New England Journal of Medicine in 2022.
- Compounded
- Made to order by a pharmacy for an individual patient rather than manufactured and approved as a finished product. Compounded drugs are not FDA-approved and the FDA has not evaluated their safety, effectiveness or quality.
Compare
Others selling what Luvo Health sells
Companies we have also reviewed that dispense at least one of the same compounds, ordered by how much of what they say about their products matches the trials behind them. Nothing here is a recommendation, and none of these links earns us anything.
Ranked
The lists Luvo Health is on
Method
How we checked this
Non-product facts last checked September 2026. Read the editorial policy for the rules this page is held to.
Read our methodology
Claims read first-party
Every quoted claim was read off Luvo Health's own pages, first-hand, on the date stamped against it — never from a summary, an aggregator, or an earlier version of this review.
Trials read from the registry
Phase, status and enrollment come from ClinicalTrials.gov; identifiers and journals from PubMed's own records. Nothing here is cited from memory.
Absence claims bounded
Where we report that no trial exists, the page says what was searched, where, and when — never an unbounded claim that nobody has tested something.
Letters matched on full name
FDA letters are matched on the complete company name. A substring match would attach one firm's regulatory history to another with a similar name.
Sources
References
Show all 3 sources
- Wilding JPH, Batterham RL, Calanna S, et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1) — 1,961 adults over 68 weeks, with weight still falling at the end of the trial. New England Journal of Medicine. https://clinicaltrials.gov/study/NCT03548935
- Jastreboff AM, Aronne LJ, Ahmad NN, et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1) — 2,539 adults over 72 weeks at 5, 10 and 15 mg once weekly. New England Journal of Medicine. https://clinicaltrials.gov/study/NCT04184622
- Publisher (2026). Public buyer information checked October 13, 2026. Public primary source. the Luvo Health site
Medical disclaimer: This content is for general educational purposes only and is not medical advice, diagnosis, or treatment. Always consult a licensed healthcare professional before starting, stopping, or changing any treatment.